MiNK Therapeutics Announces Publication of Landmark Case with Allogeneic iNKT Cell Therapy

Strategic Insights -

A groundbreaking case study has been published by MiNK Therapeutics, highlighting the potential of their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in treating cancer. The patient, who had exhausted all standard and experimental treatments, achieved a complete clinical, radiologic, and biochemical remission after receiving a single infusion of agenT-797 alongside nivolumab. The case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.

Key Takeaways:

  • MiNK Therapeutics' allogeneic iNKT cell therapy, agenT-797, achieved a complete clinical, radiologic, and biochemical remission in a patient with heavily pretreated germ cell tumor.
  • The patient had progressed after multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4, and anti-TIGIT).
  • AgenT-797 was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).
  • Donor iNKT cells were detectable up to six months post-infusion.
  • This case demonstrates the potential of agenT-797 to reshape the tumor microenvironment and deliver durable clinical activity, even in heavily pretreated, immunotherapy-resistant cancers.
  • MiNK's clinical trial (NCT05108623) showed a remarkable response in a patient who had exhausted standard and experimental treatments.
  • Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners, commented on the powerful potential of iNKT cells in treating even the most challenging cancers.

Statistics:

  • 2-year remission achieved in a patient with heavily pretreated germ cell tumor.
  • 6 months post-infusion, donor iNKT cells were detectable.
  • AgenT-797 was well-tolerated with no CRS or GVHD.
  • 12 months of extended survival observed in several patients in Phase 2 trial in 2L gastric cancer.
  • 42% tumor reduction achieved in a patient with metastatic gastric cancer following a single infusion of agenT-797 in combination with nivolumab.
  • NCT06251973 is the ongoing Phase 2 trial in gastric cancer, actively enrolling with additional readouts expected in upcoming months.

Sources:

  • (GLOBE NEWSWIRE) - "MiNK Therapeutics Announces Publication of Landmark Case with Allogeneic iNKT Cell Therapy"
  • "Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor" (published in )
  • NCT05108623 - "A Study of AgenT-797 in Combination with Nivolumab in Participants With Advanced or Metastatic Solid Tumors"
  • NCT06251973 - "A Study of AgenT-797 in Combination with Nivolumab in Participants With Advanced or Metastatic Gastric Cancer"
  • Oncogene - "AgenT-797 Induces Tumor Reduction and Immune Activation in Patients with Metastatic Gastric Cancer"
  • (Nature Communications) - "Severe Respiratory Pathology: AgenT-797 in Combination with Nivolumab Reduces Inflammation"